Compare Abeona Therapeutics Inc (ABEO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs IDEXX Laboratories, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while IDEXX Laboratories, Inc. trades at $558.24 (market cap $44.98B). The key difference: IDEXX Laboratories, Inc. is far larger — about 120.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | IDXX | |
|---|---|---|
Market Cap | $373.32M | $44.98B |
Sector | Health | Health |
52-Week High | $7.23 | $766.68 |
52-Week Low | $4.17 | $514.61 |
Enterprise Value | $228.22M | $45.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IDXX trades at $570.25, up 2.23% today, with strong technical momentum as it approaches resistance near $572. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics. Analyst sentiment is bullish with a $645 consensus target, though elevated valuations pose a risk.
Outlook remains positive given consistent earnings beats and strategic AI integration, but high P/E of 41.57 suggests limited margin for error. Key risks include competitive pressures and reliance on pet healthcare spending cycles. Institutional ownership trends and upcoming Q2 earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
